LNTH · Lantheus Holdings, Inc.
$100.77
+0.30 (+0.30%)
At close · Aug 28
Market Cap
$6.58B
Shares
65.27M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$100.77
Open$100.71
Day$100.38–100.91
52W close$50.11–110.94
Avg vol 30d1.8M
Short int5.1M · 7.9% float · 1.8d
Short vol15%
Last earningsAug 6, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 6, 2026
Est · unconfirmed
· in 10 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 6, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very Low
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+21%
above
Price vs 50-day avg
−3%
below
RSI (14)
47
neutral
MACD trend
Positive
52-week position
83%
mid-range
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+26%
trailing
YTD return
+51%
this year
Relative strength
+13%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $104 › 200d $83 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +98 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.85% of float · ▼ -18.8% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
468 holders — mid 3-yr range
Squeeze score
50
elevated · 0–100
Fundamentals
Revenue growth
+4%
Y/Y
Gross margin
274%
contracting
EPS growth
−22%
Y/Y
Valuation
P/E 24.1
in line
Buyback
$200.0M
remaining
Balance sheet
$210.3M
net debt
Quant / Vol
risk profile
Volatility
35%
annualized · 1-yr
Max drawdown
−13%
past year
ATR
1.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
FY 2026 Revenue
· FY 2026
Initiated
$1.4B – $1.45B
prior FY $1.54B
midpoint −7.6% Y/Y
FY 2026 Adjusted fully diluted EPS
· FY 2026
Non-GAAP
Initiated
$5.00 – $5.25
Prior guidance
period ended
· from the 8-K filed Nov 6, 2025
FY 2025 Revenue
· FY 2025
$1.49B – $1.51B
FY 2025 Adjusted fully diluted EPS
· FY 2025
$5.50 – $5.65
Guided vs delivered
· last 8 settled
FY 2025 Revenue
FY 2025
guided $1.49B – $1.51B
$1.54B
Beat +2.8%
FY 2024 Revenue
FY 2024
guided $1.51B – $1.52B
$1.53B
Beat +1.2%
Net revenue
second quarter
guided $380M – $390M
$394.09M
Beat +2.4%
Net revenue
first quarter 2024
guided $347M – $355M
$369.98M
Beat +5.4%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+21%
Bullish
Price vs 50-day avg
−3%
Neutral
RSI (14)
47
Neutral
MACD trend
Positive
Bullish
52-week position
83%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $104 › 200d $83 — 50d above 200d
Institutional flow
Accumulating
+14% holders QoQ · +98 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
7.85% of float · ▼ -18.8% MoM · 1.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
468 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $50
Now $101 · 83%
Range high $111
vs 200-day avg +21%
vs 50-day avg -3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net income, as a percentage of revenues non-GAAP | 26.2% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted operating income (non-GAAP) non-GAAP | $142M | Q2 2026 | — |
|
|
|||
| Adjusted operating income, as a percentage of revenues non-GAAP | 35.4% | Six Months Ended June 30, 2026 | — |
|
|
|||
| Free cash flow | 211.77M | Six Months Ended June 30 | — |
|
|
|||
| Sales of DEFINITY | $88.3M | Q2 2026 | +5.2% |
|
|
|||
| Sales of Neuraceq | $39.6M | Q2 2026 | — |
|
|
|||
| Sales of PYLARIFY | $240.4M | Q2 2026 | -4.1% |
|
|
|||
| Adjusted net income non-GAAP | 95.8M | Three Months Ended March 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net income 118.42M
+16.04M Stock and incentive plan compensation
+16.72M Amortization of acquired intangible assets
+12K Campus consolidation costs
-358K Contingent consideration fair value adjustments
+7.41M Non-recurring fees
-59.33M Gain on sale of business, net of transaction costs
-131K Strategic collaboration and license costs
-14.91M Investment in equity securities - unrealized (gain) loss
+6.37M Acquisition, integration and divestiture-related items
+80K Other
+5.47M Income tax effect of non-GAAP adjustments
= Adjusted net income 95.8M
|
|||
| Adjusted net income per share - diluted non-GAAP | $1.46 | Three Months Ended March 31, 2026 | — |
| Adjusted operating income non-GAAP | 129.15M | Three Months Ended March 31, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Operating income 81.33M
+16.04M Stock and incentive plan compensation
+16.72M Amortization of acquired intangible assets
+12K Campus consolidation costs
-358K Contingent consideration fair value adjustments
+7.41M Non-recurring fees
-131K Strategic collaboration and license costs
+8.04M Acquisition, integration and divestiture-related items
+80K Other
= Adjusted operating income 129.15M
|
|||
| Net cash provided by operating activities | $90.2M | Q4 FY2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LNTH
this stock
Lantheus Holdings, Inc.
|
$6.58B | +51.4% | +3.6% | 24.1 | 7.9% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.59B | +15.7% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$49.38B | +2.2% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.46B | +0.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LNTH | +0.8% | +1.1% | +26.0% | +1.1% | +51.4% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +0.3% | -1.9% | +12.5% | -1.9% | +38.6% |
Capital returns
Buyback program
· as of Jun 30, 2026
Authorized
$400.00M
Spent (derived)
$200.00M
Remaining
$200.00M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1521036
CUSIP
516544103
13F (30d)
333 filings
329 filers
Visit website
Investor relations